CNBC November 12, 2024
Ashley Capoot

Key Points

– 23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier.

– The embattled genetics company said Monday that it’s cutting about 200 jobs, or about 40% of its workforce, and discontinuing its therapeutics programs.

– Shares in the company are down 75% this year after losing more than half their value in 2023.

23andMe on Tuesday reported declining revenue in its most recent quarter, a day after the company said it will cut 40% of its workforce and shutter its therapeutics business as part of a business restructuring plan.

The embattled genetics company reported $44.1 million in revenue for the fiscal second quarter, down from $50 million in the same...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma / Biotech, Precision Medicine
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Oncologist talks personalized medicine for pancreatic cancer
AI offers a step above genomic solutions
How Mayo Clinic is using real-world data to advance precision medicine
Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Share This Article